JP2020505354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505354A5 JP2020505354A5 JP2019538615A JP2019538615A JP2020505354A5 JP 2020505354 A5 JP2020505354 A5 JP 2020505354A5 JP 2019538615 A JP2019538615 A JP 2019538615A JP 2019538615 A JP2019538615 A JP 2019538615A JP 2020505354 A5 JP2020505354 A5 JP 2020505354A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- pyrido
- indole
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- -1 indole-2-yl Chemical group 0.000 claims 5
- BTJWAAQFFCCLEV-DDWQGHIRSA-N (2R)-3-[(1R,3R)-1-[3-[2-(3,3-difluoropropylamino)ethoxy]-6-fluoro-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCC(F)F)=CC=C1F)C(O)=O BTJWAAQFFCCLEV-DDWQGHIRSA-N 0.000 claims 1
- JMHAEPDWKOSCPH-RYUVBPIJSA-N (2R)-3-[(1R,3R)-1-[5-fluoro-2-[2-(3-fluoropropylamino)ethoxy]-3-methylpyridin-4-yl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=NC=C1F)C(O)=O JMHAEPDWKOSCPH-RYUVBPIJSA-N 0.000 claims 1
- KNSMOAXIFSMQRE-KMVLGAPJSA-N (2R)-3-[(1R,3R)-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=CC=C1F)C(O)=O KNSMOAXIFSMQRE-KMVLGAPJSA-N 0.000 claims 1
- OUWDZJIZWQEYKX-BIALHBOASA-N (2R)-3-[(1R,3R)-1-[6-fluoro-3-[2-[3-fluoropropyl(methyl)amino]ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)Cc2c([nH]c3ccccc23)[C@H]1c1c(F)ccc(OCCN(C)CCCF)c1C)C(O)=O OUWDZJIZWQEYKX-BIALHBOASA-N 0.000 claims 1
- JOFYCYZGTXIWEJ-DDWQGHIRSA-N (2R)-3-[(1R,3R)-6-fluoro-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@H](CN1[C@H](C)CC2=C(NC3=CC=C(F)C=C23)[C@H]1C1=C(C)C(OCCNCCCF)=CC=C1F)C(O)=O JOFYCYZGTXIWEJ-DDWQGHIRSA-N 0.000 claims 1
- BTJWAAQFFCCLEV-ANAQZDLVSA-N (2S)-3-[(1R,3R)-1-[3-[2-(3,3-difluoropropylamino)ethoxy]-6-fluoro-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCC(F)F)=CC=C1F)C(O)=O BTJWAAQFFCCLEV-ANAQZDLVSA-N 0.000 claims 1
- JMHAEPDWKOSCPH-RJYGXOMWSA-N (2S)-3-[(1R,3R)-1-[5-fluoro-2-[2-(3-fluoropropylamino)ethoxy]-3-methylpyridin-4-yl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=NC=C1F)C(O)=O JMHAEPDWKOSCPH-RJYGXOMWSA-N 0.000 claims 1
- KNSMOAXIFSMQRE-HQWTYURQSA-N (2S)-3-[(1R,3R)-1-[6-fluoro-3-[2-(3-fluoropropylamino)ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)CC2=C(NC3=CC=CC=C23)[C@H]1C1=C(C)C(OCCNCCCF)=CC=C1F)C(O)=O KNSMOAXIFSMQRE-HQWTYURQSA-N 0.000 claims 1
- JGCBBJPNCBOABY-QLPUUCHCSA-N (2S)-3-[(1R,3R)-6-fluoro-1-[6-fluoro-3-[2-[3-fluoropropyl(methyl)amino]ethoxy]-2-methylphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methylpropanoic acid Chemical compound C[C@@H](CN1[C@H](C)Cc2c([nH]c3ccc(F)cc23)[C@H]1c1c(F)ccc(OCCN(C)CCCF)c1C)C(O)=O JGCBBJPNCBOABY-QLPUUCHCSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OUWDZJIZWQEYKX-IRSBVZMGSA-N FC1=CC=C(C(=C1[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)C[C@@H](C(=O)O)C)C)OCCN(C([2H])([2H])[2H])CCCF Chemical compound FC1=CC=C(C(=C1[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)C[C@@H](C(=O)O)C)C)OCCN(C([2H])([2H])[2H])CCCF OUWDZJIZWQEYKX-IRSBVZMGSA-N 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451971P | 2017-01-30 | 2017-01-30 | |
| US62/451,971 | 2017-01-30 | ||
| US201762523695P | 2017-06-22 | 2017-06-22 | |
| US62/523,695 | 2017-06-22 | ||
| US201762560304P | 2017-09-19 | 2017-09-19 | |
| US62/560,304 | 2017-09-19 | ||
| US201762592485P | 2017-11-30 | 2017-11-30 | |
| US62/592,485 | 2017-11-30 | ||
| PCT/EP2018/052040 WO2018138303A1 (en) | 2017-01-30 | 2018-01-29 | Estrogen receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505354A JP2020505354A (ja) | 2020-02-20 |
| JP2020505354A5 true JP2020505354A5 (enExample) | 2020-11-12 |
| JP6951451B2 JP6951451B2 (ja) | 2021-10-20 |
Family
ID=61223883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538615A Active JP6951451B2 (ja) | 2017-01-30 | 2018-01-29 | エストロゲン受容体モジュレーター |
Country Status (35)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| TWI915239B (zh) * | 2018-06-21 | 2026-02-11 | 瑞士商赫孚孟拉羅股份公司 | 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法 |
| US20220370625A1 (en) * | 2019-09-19 | 2022-11-24 | Totus Medicines Inc. | Therapeutic conjugates |
| AU2022233254A1 (en) | 2021-03-11 | 2023-10-26 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| CN115557920B (zh) * | 2022-09-22 | 2024-02-20 | 吉林奥来德光电材料股份有限公司 | 一种发光辅助材料、其制备方法及有机电致发光器件 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP4555547B2 (ja) | 2000-08-10 | 2010-10-06 | ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ | キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物 |
| EP1746157A4 (en) * | 2004-04-27 | 2009-02-18 | Chugai Pharmaceutical Co Ltd | PROCESS FOR PLASMA CELL PROGRAMMING |
| WO2006101434A1 (en) | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| HUE052510T2 (hu) | 2009-05-27 | 2021-05-28 | Ptc Therapeutics Inc | Módszerek a rák és a nem daganatos állapotok kezelésére |
| US20120157402A1 (en) | 2009-05-27 | 2012-06-21 | Liangxian Cao | Methods for treating brain tumors |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| PE20160874A1 (es) | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| CN117865872A (zh) | 2014-12-18 | 2024-04-12 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| JP2017538727A (ja) | 2014-12-18 | 2017-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌の治療に有用な２，３−ジフェニルクロメンの誘導体 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| EP3303326B1 (en) | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| KR20180012853A (ko) | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| DK3355884T3 (da) | 2015-10-01 | 2021-08-02 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler |
| CN108349952A (zh) | 2015-11-09 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| CA3011391C (en) | 2015-11-12 | 2021-02-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| HK1244808A1 (zh) | 2015-12-22 | 2018-08-17 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
| US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
| CN109415388A (zh) | 2016-05-06 | 2019-03-01 | 路易斯安那泽维尔大学 | 选择性雌激素受体下调剂(serds) |
| CN109415361B (zh) | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| US10149839B2 (en) * | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
| JOP20190090B1 (ar) | 2016-10-24 | 2023-03-28 | Astrazeneca Ab | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｊａｋファミリーのキナーゼの低分子阻害物質 |
| US20200077658A1 (en) | 2016-12-16 | 2020-03-12 | Basf Se | Pesticidal Compounds |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| PH12019501328B1 (en) | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| GEP20207202B (en) | 2017-01-30 | 2020-12-25 | Chiesi Farm Spa | Tyrosine amide derivatives as rho-kinase inhibitors |
-
2018
- 2018-01-29 EP EP19203383.5A patent/EP3689873B1/en active Active
- 2018-01-29 MA MA052555A patent/MA52555A/fr unknown
- 2018-01-29 DK DK18705097.6T patent/DK3494116T3/da active
- 2018-01-29 MX MX2019008438A patent/MX2019008438A/es unknown
- 2018-01-29 AU AU2018211495A patent/AU2018211495B2/en active Active
- 2018-01-29 PL PL18705097T patent/PL3494116T3/pl unknown
- 2018-01-29 WO PCT/EP2018/052040 patent/WO2018138303A1/en not_active Ceased
- 2018-01-29 LT LTEP18705097.6T patent/LT3494116T/lt unknown
- 2018-01-29 PT PT187050976T patent/PT3494116T/pt unknown
- 2018-01-29 JP JP2019538615A patent/JP6951451B2/ja active Active
- 2018-01-29 MY MYPI2019004298A patent/MY196317A/en unknown
- 2018-01-29 JO JOP/2019/0183A patent/JOP20190183B1/ar active
- 2018-01-29 TW TW107103088A patent/TWI794205B/zh active
- 2018-01-29 SI SI201830022T patent/SI3494116T1/sl unknown
- 2018-01-29 CR CR20190379A patent/CR20190379A/es unknown
- 2018-01-29 UA UAA201909412A patent/UA125043C2/uk unknown
- 2018-01-29 US US15/881,962 patent/US10221173B2/en active Active
- 2018-01-29 RS RS20200018A patent/RS59770B1/sr unknown
- 2018-01-29 PE PE2019001434A patent/PE20191500A1/es unknown
- 2018-01-29 CN CN201880008715.8A patent/CN110214140B/zh active Active
- 2018-01-29 TN TNP/2020/000009A patent/TN2020000009A1/en unknown
- 2018-01-29 ES ES19203383T patent/ES2931320T3/es active Active
- 2018-01-29 HU HUE18705097A patent/HUE047761T2/hu unknown
- 2018-01-29 EP EP18705097.6A patent/EP3494116B1/en active Active
- 2018-01-29 KR KR1020197025253A patent/KR102246668B1/ko active Active
- 2018-01-29 ES ES18705097T patent/ES2766249T3/es active Active
- 2018-01-29 SG SG11201906767XA patent/SG11201906767XA/en unknown
- 2018-01-29 SM SM20200010T patent/SMT202000010T1/it unknown
-
2019
- 2019-01-31 US US16/263,683 patent/US10590132B2/en active Active
- 2019-07-15 CL CL2019001991A patent/CL2019001991A1/es unknown
- 2019-07-16 DO DO2019000183A patent/DOP2019000183A/es unknown
- 2019-07-17 ZA ZA2019/04696A patent/ZA201904696B/en unknown
- 2019-07-25 IL IL268263A patent/IL268263B/en unknown
- 2019-07-26 PH PH12019501724A patent/PH12019501724A1/en unknown
- 2019-07-26 NI NI201900080A patent/NI201900080A/es unknown
- 2019-08-16 CO CONC2019/0008941A patent/CO2019008941A2/es unknown
- 2019-08-28 EC ECSENADI201962381A patent/ECSP19062381A/es unknown
-
2020
- 2020-01-08 CY CY20201100014T patent/CY1122731T1/el unknown
- 2020-01-29 US US16/775,781 patent/US11046689B2/en active Active